Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: A prospective observational study

The Lancet Oncology

Volumn 12, Issue 6, 2011, Pages 559-567

  Villani, Anita ^a   Tabori, Uri ^a   Schiffman, Joshua ^b   Shlien, Adam ^a   Beyene, Joseph ^c   Druker, Harriet ^a   Novokmet, Ana ^a   Finlay, Jonathan ^d   Malkin, David ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CANCER RISK; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FAMILIAL CANCER; FEASIBILITY STUDY; FEMALE; FUNDING; GENE; GENE MUTATION; GENETIC ANALYSIS; GLIOMA; HUMAN; MALE; MYELODYSPLASTIC SYNDROME; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; THYROID ADENOMA; TP53 GENE;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; INFANT; INFANT, NEWBORN; LI-FRAUMENI SYNDROME; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79957474904     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70119-X     Document Type: Article

References (45)

1. Nichols KE, Malkin D, Garber JE, Fraumeni JF, Li FP Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev 2001, 10:83-87.
2. Birch JM, Alston RD, McNally RJ, et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 2001, 20:4621-4628.
3. Li FP, Fraumeni JF, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988, 48:5358-5362.
4. Birch JM, Hartley AL, Tricker KJ, et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 1994, 54:1298-1304.
5. Eeles RA Germline mutations in the TP53 gene. Cancer Surv 1995, 25:101-124.
6. Tinat J, Bougeard G, Baert-Desurmont S, et al. 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 2009, 27:e108-e109.
7. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990, 250:1233-1238.
8. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990, 348:747-749.
9. Varley JM, McGown G, Thorncroft M, et al. Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res 1997, 57:3245-3252.
10. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002, 19:607-614.
11. Bougeard G, Sesboue R, Baert-Desurmont S, et al. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet 2008, 45:535-538.
12. Gonzalez KD, Noltner KA, Buzin CH, et al. Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 2009, 27:1250-1256.
13. Chompret A, Brugieres L, Ronsin M, et al. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer 2000, 82:1932-1937.
14. Tischkowitz M, Rosser E Inherited cancer in children: practical/ethical problems and challenges. Eur J Cancer 2004, 40:2459-2470.
15. Hisada M, Garber JE, Fung CY, Fraumeni JF, Li FP Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998, 90:606-611.
16. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 2003, 21:2397-2406. American Society of Clinical Oncology.
17. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian V.I.2010 NCCN Genetic/Familial High-Risk Assessment Panel, (accessed April 4, 2011). http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf.
18. Goo HW, Choi SH, Ghim T, Moon HN, Seo JJ Whole-body MRI of paediatric malignant tumours: comparison with conventional oncological imaging methods. Pediatr Radiol 2005, 35:766-773.
19. Rees J Advances in magnetic resonance imaging of brain tumours. Curr Opin Neurol 2003, 16:643-650.
20. Allolio B, Fassnacht M Clinical review: adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 2006, 91:2027-2037.
21. Luta G, Koch GG, Cascio WE, Smith WT An application of methods for clustered binary responses to a cardiovascular study with small sample size. J Biopharm Stat 1998, 8:87-102.
22. Wei LJ, Lin DY, Weissfeld L Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc 1989, 84:1065-1073.
23. Tabori U, Shlien A, Baskin B, et al. TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors. J Clin Oncol 2010, 28:1995-2001.
24. Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. Am J Hum Genet 1995, 57:1233-1241. American Society of Human Genetics Board of Directors, American College of Medical Genetics Board of DirectorsAmerican College of Medical Genetics Board of Directors.
25. Li FP Identification and management of inherited cancer susceptibility. Environ Health Perspect 1995, 103(suppl 8):297-300.
26. Ethical issues with genetic testing in pediatrics. Pediatrics 2001, 107:1451-1455. American Academy of Pediatrics, Committee on BioethicsCommittee on Bioethics.
27. Evans DG, Lunt P, Clancy T, Eeles R Childhood predictive genetic testing for Li-Fraumeni syndrome. Fam Cancer 2010, 9:65-69.
28. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001, 86:5658-5671.
29. Field M, Shanley S, Kirk J Inherited cancer susceptibility syndromes in paediatric practice. J Paediatr Child Health 2007, 43:219-229.
30. Jenkins MA, Croitoru ME, Monga N, et al. Risk of colorectal cancer in monoallelic and biallelic carriers of MYH mutations: a population-based case-family study. Cancer Epidemiol Biomarkers Prev 2006, 15:312-314.
31. Arbour L Guidelines for genetic testing of healthy children. Paediatr Child Health 2003, 8:42-45. Canadian Paediatric Society BC, Canadian College of Medical GeneticistsCanadian College of Medical Geneticists, Ethics and Public Policy CommitteeEthics and Public Policy Committee.
32. Le Bihan C, Moutou C, Brugieres L, Feunteun J, Bonaiti-Pellie C ARCAD: a method for estimating age-dependent disease risk associated with mutation carrier status from family data. Genet Epidemiol 1995, 12:13-25.
33. Varley JM Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat 2003, 21:313-320.
34. Limacher JM, Frebourg T, Natarajan-Ame S, Bergerat JP Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer 2001, 96:238-242.
35. Sproston AR, Boyle JM, Heighway J, Birch JM, Scott D Fibroblasts from Li-Fraumeni patients are resistant to low dose-rate irradiation. Int J Radiat Biol 1996, 70:145-150.
36. Royds JA, Iacopetta B p53 and disease: when the guardian angel fails. Cell Death Differ 2006, 13:1017-1026.
37. Lammens CR, Aaronson NK, Wagner A, et al. Genetic testing in li-fraumeni syndrome: uptake and psychosocial consequences. J Clin Oncol 2010, 28:3008-3014.
38. Masciari S, Van den Abbeele AD, Diller LR, et al. F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. JAMA 2008, 299:1315-1319.
39. Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005, 365:1769-1778.
40. Lin MT, Shieh JJ, Chang JH, Chang SW, Chen TC, Hsu WH Early detection of adrenocortical carcinoma in a child with Li-Fraumeni syndrome. Pediatr Blood Cancer 2009, 52:541-544.
41. Tabori U, Malkin D Risk stratification in cancer predisposition syndromes: lessons learned from novel molecular developments in Li-Fraumeni syndrome. Cancer Res 2008, 68:2053-2057.
42. Bougeard G, Baert-Desurmont S, Tournier I, et al. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 2006, 43:531-533.
43. Marcel V, Palmero EI, Falagan-Lotsch P, et al. TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis. J Med Genet 2009, 46:766-772.
44. Tabori U, Nanda S, Druker H, Lees J, Malkin D Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome. Cancer Res 2007, 67:1415-1418.
45. Trkova M, Prochazkova K, Krutilkova V, Sumerauer D, Sedlacek Z Telomere length in peripheral blood cells of germline TP53 mutation carriers is shorter than that of normal individuals of corresponding age. Cancer 2007, 110:694-702.